Indivior PLC (NASDAQ:INDV) Receives Average Recommendation of “Buy” from Analysts

Indivior PLC (NASDAQ:INDV) has earned a consensus recommendation of “Buy” from the seven research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $39.3333.

A number of equities analysts have recently issued reports on the company. HC Wainwright increased their target price on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Weiss Ratings lowered Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, March 17th. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Finally, Northland Securities set a $50.00 price objective on Indivior in a report on Tuesday, January 20th.

Insider Activity

In other news, Director Stuart A. Kingsley bought 940 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was acquired at an average price of $31.86 per share, for a total transaction of $29,948.40. Following the transaction, the director directly owned 5,582 shares of the company’s stock, valued at $177,842.52. This trade represents a 20.25% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.74% of the stock is owned by company insiders.

Institutional Trading of Indivior

Several hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its stake in shares of Indivior by 18.4% in the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after acquiring an additional 1,299,425 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Indivior by 2,597.9% in the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after acquiring an additional 958,132 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Indivior by 669.1% in the second quarter. JPMorgan Chase & Co. now owns 391,386 shares of the company’s stock valued at $5,769,000 after acquiring an additional 340,498 shares during the last quarter. Prudential Financial Inc. bought a new position in shares of Indivior in the second quarter valued at approximately $207,000. Finally, Walleye Capital LLC bought a new position in shares of Indivior in the second quarter valued at approximately $594,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Stock Performance

Shares of Indivior stock opened at $34.15 on Thursday. The firm has a market cap of $4.16 billion, a P/E ratio of 20.82 and a beta of 0.88. The firm’s 50-day simple moving average is $31.79 and its 200-day simple moving average is $32.38. Indivior has a twelve month low of $10.63 and a twelve month high of $38.00.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Friday, February 27th. The company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.17. The firm had revenue of $358.00 million during the quarter, compared to analyst estimates of $305.62 million. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. On average, equities analysts forecast that Indivior will post 3 earnings per share for the current fiscal year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.